Company Filing History:
Years Active: 2017
Title: Innovations of Mripen Chanda in Peptide Technology
Introduction
Mripen Chanda is an accomplished inventor based in Columbia, MO (US). He has made significant contributions to the field of peptide technology, particularly in the development of peptides with specific binding affinities. His work has implications for medical diagnostics and therapeutic applications.
Latest Patents
Mripen Chanda holds a patent for a peptide with gold binding and EGFR receptor affinity. This invention includes a peptide comprising four distinct domains. Domain I consists of thioctyl or monocytl, while domain II includes 2 to 3 positively charged amino acids selected from lysine and arginine. Domain III features a dimeric ethylene unit, and domain IV comprises the peptide with SEQ ID No. 1 or a sequence having at least 90% identity to SEQ ID No. 1. The peptide is preferably attached to a gold nanostructure, specifically a gold nanorod, to create an EGFR detection kit. This kit employs a gold nanostructure attached to a peptide sequence that includes a binding sequence with an affinity toward EGFR, a ligand bound to gold atoms of the nanorod, a positively charged amino acid that maintains the activity of the binding sequence, and a unit that increases the hydrophilicity of the peptide sequence.
Career Highlights
Mripen Chanda is affiliated with the University of Missouri, where he continues to advance his research in peptide technology. His innovative work has garnered attention in the scientific community, contributing to the understanding of peptide interactions and their applications in diagnostics.
Collaborations
Mripen has collaborated with notable colleagues, including Charles W Caldwell, Jr. and Raghuraman Kannan. These collaborations have further enriched his research and expanded the impact of his inventions.
Conclusion
Mripen Chanda's contributions to peptide technology exemplify the intersection of innovation and practical application in the medical field. His patented work on peptides with gold binding and EGFR receptor affinity showcases the potential for advancements in diagnostic tools.